Spexin: Complete Research Profile — The GALR2/GALR3-Activating Neuropeptide, Obesity Biomarker, and Metabolic Disease Research (2026)

# Spexin: Complete Research Profile — The GALR2/GALR3-Activating Neuropeptide, Obesity Biomarker, and Metabolic Disease Research (2026)

Some neuropeptide discoveries emerge from the laboratory bench through biochemical purification or serendipitous observation. Others emerge from the genome itself — identified by algorithms that mine vertebrate sequences for conserved peptide-encoding open reading frames. Spexin (SPX) belongs to the second category. Discovered in 2013 through comparative genomics, spexin turned out to be a broadly expressed 14-amino acid peptide that activates galanin receptors GALR2 and GALR3 with selectivity not shared by galanin itself — and whose circulating levels are markedly reduced in obesity, type 2 diabetes, and cardiovascular disease, establishing it as one of the most compelling metabolic biomarker peptides identified in the past decade.

Discovery: Phylogenomics and the SPX Gene

Computational Discovery (2013)

Olivier Mirabeau and Nicolas Bhatt independently identified spexin through phylogenomics — a strategy of comparing genomes across multiple vertebrate species to identify conserved peptide precursor sequences that might have been missed by classical biochemistry. Their 2013 analysis in Nature Chemical Biology demonstrated that:

• •The gene C12orf39 (chromosome 12 open reading frame 39) in humans encoded a predicted preproprotein with a signal peptide, dibasic cleavage sites, and a C-terminal amidation signal
• •The predicted active peptide sequence was phylogenetically conserved across vertebrates from fish to mammals
• •The peptide showed structural relatedness to the galanin/allatostatin peptide family (a large family of invertebrate neuropeptides and their vertebrate descendants)
• •Receptor activation assays in cells expressing galanin receptor subtypes identified GALR2 and GALR3 as spexin receptors

The gene was renamed SPX (spexin) following the functional characterization.

The Name

"Spexin" was derived from SPinal cord-expressed — reflecting early observations of high expression in the dorsal horn — combined with "-in" (the conventional neuropeptide suffix). However, subsequent expression profiling revealed spexin is expressed far more broadly than the spinal cord alone.

Molecular Biology: SPX Gene and Peptide Structure

Precursor Processing

The SPX gene encodes a 115-amino acid preproprotein (prepro-spexin) that undergoes:

1. N-terminal signal peptide cleavage (secretory pathway)

2. Dibasic protease cleavage (furin/PC enzymes) at Arg-Arg and Arg-Lys sites flanking the active sequence

3. C-terminal amidation (PAM enzyme) — required for biological activity

The resulting mature spexin-14 consists of 14 amino acids:

NWTPQAMLYLKGAQ-NH₂ (human spexin)

This sequence is C-terminally amidated (-NH₂), as with most bioactive neuropeptides (CCK, NPY, galanin, phoenixin, etc.).

Phylogenetic Conservation

Spexin sequences from fish (Danio rerio, Oryzias latipes), amphibians (Xenopus), reptiles, birds, and mammals share high C-terminal identity, particularly the -MLYLKGAQ-NH₂ core. This conservation across ~500 million years of vertebrate evolution indicates functional constraint — the peptide performs essential functions that cannot tolerate sequence drift.

Interestingly, a BLAST-searchable spexin ortholog is also found in arthropods (related to allatostatins — insect peptides regulating juvenile hormone synthesis), connecting spexin to an evolutionarily ancient peptide regulatory system.

Receptor Pharmacology: GALR2 and GALR3

Galanin Receptor Family Context

The galanin receptor family comprises three subtypes:

• •GALR1: Primary galanin receptor; inhibitory (Gαi-coupled); expressed in CNS (spinal cord, cortex, hippocampus, brainstem), gut, adrenal
• •GALR2: Gαq (and Gαi in some tissues); expressed in CNS, DRG, pituitary, reproductive tissues
• •GALR3: Gαi-coupled; expressed in CNS, DRG, gut, metabolic tissues

Galanin activates all three subtypes (GALR1 = GALR2 > GALR3 in affinity).

Spexin's GALR2/GALR3 Selectivity

The critical pharmacological distinction: spexin does NOT activate GALR1 at physiologically relevant concentrations. Spexin shows selective agonism at GALR2 and GALR3, with Ki values in the nanomolar range for both receptors and negligible GALR1 activity.

This selectivity matters because:

• •GALR1 mediates many of galanin's actions in the hippocampus and spinal cord (including those related to memory impairment and pain facilitation)
• •GALR2 mediates distinct effects including pain inhibition, anti-depressant-like actions, and metabolic regulation
• •GALR3 is less-characterized but implicated in metabolic regulation and fear/anxiety

Spexin thus provides pharmacological access to the GALR2/GALR3 pharmacology without the GALR1-mediated confounds — making it a valuable tool for dissecting galanin receptor subtype-specific biology.

Signal Transduction

GALR2 signaling (via spexin):

• •Gαq → PLCβ → IP3/DAG → Ca²⁺ mobilization and PKC activation
• •ERK1/2 phosphorylation
• •Also Gαi/cAMP inhibition in some cellular contexts

GALR3 signaling (via spexin):

• •Primarily Gαi → inhibition of adenylyl cyclase → reduced cAMP
• •GIRK channel activation → membrane hyperpolarization

The dual Gαq (GALR2) and Gαi (GALR3) coupling gives spexin a complex pharmacological profile depending on the relative GALR2:GALR3 receptor complement in target tissue.

Expression Pattern

Spexin mRNA and protein are broadly distributed:

CNS:

• •Spinal cord dorsal horn (highest CNS levels; hence the original name)
• •Hypothalamus (arcuate nucleus, paraventricular nucleus)
• •Cortex
• •Hippocampus (dentate gyrus)
• •Cerebellum

Endocrine/Peripheral:

• •Pituitary (anterior and posterior)
• •Thyroid (C-cells)
• •Adrenal gland
• •Pancreatic islets (alpha and beta cells)
• •GI tract (stomach, small intestine — enteroendocrine cells)
• •Liver
• •Heart
• •Gonads (testis, ovary)
• •Adipose tissue (minimal)

This breadth of expression parallels other pleiotropic metabolic neuropeptides (VIP, galanin, nesfatin-1) that integrate CNS and peripheral signals.

Metabolic Biology: Feeding Suppression and Energy Homeostasis

Central Anorexigenic Effects

Central (ICV) spexin administration in rodents reduces food intake dose-dependently. The magnitude of effect is comparable to other GALR2-activating approaches, and is blocked by GALR2/GALR3 antagonists, confirming receptor specificity.

The likely hypothalamic mechanism involves GALR2/GALR3 on arcuate nucleus neurons — possibly inhibiting orexigenic NPY/AgRP neurons and/or facilitating POMC neuron activity, though the precise circuit-level mechanism remains under investigation.

SPX-1 Fragment and Zebrafish Model

Work in zebrafish (Danio rerio), where the spexin system is highly homologous, confirmed that spexin regulates food intake and swimming behavior through GALRs. Zebrafish SPX1 and SPX2 (two paralogs) both suppress food intake when overexpressed, and spexin-deficient zebrafish develop obesity on a high-fat diet — providing genetic confirmation of spexin's role in energy homeostasis.

Gastrointestinal Motility

Spexin in the gut (acting on enteric GALR2/GALR3) modulates GI motility — slowing gastric emptying in some preparations, potentially contributing to postprandial satiety beyond hypothalamic feeding suppression. This gut-level action is pharmacologically analogous to galanin's effects on gut motility through GALR1.

Spexin as an Obesity and Metabolic Disease Biomarker

The Obesity Correlation

Among spexin's most clinically significant findings is its consistent reduction in individuals with obesity and metabolic disease. Key findings from clinical studies (2014-2024):

Obesity: Plasma spexin is dramatically lower in obese compared to lean individuals — reductions of 50-80% in morbidly obese cohorts in some studies (Walewski et al. 2014, Obesity; PMID 24285359). The correlation between BMI and inverse spexin levels is among the most robust of any recently identified metabolic peptide.

Bariatric surgery: After Roux-en-Y gastric bypass or sleeve gastrectomy, spexin levels increase — often before significant weight loss — suggesting that caloric restriction and surgical gut manipulation restore spexin production independent of weight change.

Type 2 diabetes: Spexin is further reduced in T2D patients compared to BMI-matched non-diabetic obese individuals, with negative correlations observed with fasting glucose, HbA1c, insulin, and HOMA-IR index.

Non-alcoholic fatty liver disease (NAFLD/NASH): Spexin expression is reduced in human NAFLD liver biopsies, and correlates inversely with degree of hepatic steatosis and fibrosis — suggesting spexin may participate in liver lipid metabolism or inflammation regulation.

Cardiovascular disease: Patients with coronary artery disease have lower serum spexin compared to controls matched for cardiovascular risk factors.

Children and adolescents: Obese children and adolescents show reduced circulating spexin compared to lean peers, and spexin correlates negatively with waist circumference, fasting insulin, and triglycerides in pediatric cohorts.

Mechanistic Interpretations

The consistent association between low spexin and metabolic disease raises several research questions:

• •Is low spexin a cause of impaired satiety signaling in obesity (low GALR2/3 activation → less appetite suppression)?
• •Is low spexin a consequence of metabolic dysfunction (leptin resistance, hyperinsulinemia, or inflammatory cytokines suppressing SPX gene expression)?
• •Could spexin restoration serve as a therapeutic target to improve satiety signaling in obese individuals?

Preclinical data favoring a causal role: spexin supplementation in DIO mice reduces body weight and improves glucose tolerance, suggesting that the low-spexin state in obesity may functionally contribute to the metabolic phenotype rather than merely reflecting it.

Spexin in Reproductive Biology

GALR2 is expressed in pituitary gonadotrophs, and gonadal tissues (testis Leydig cells, ovarian granulosa cells). Spexin research in reproductive contexts has documented:

• •Spexin modulates LH and FSH secretion in some models (both stimulatory and inhibitory effects depending on dose and condition)
• •Spexin expression in the testis is regulated by testosterone — creating a feedback loop between androgen status and SPX production
• •Ovarian spexin expression changes across the estrous cycle, with peaks correlating with LH surge timing in some rodent studies
• •Polycystic ovary syndrome (PCOS): several studies report reduced serum spexin in PCOS patients, with correlations to androgen levels and insulin resistance

Pain Modulation: GALR2 in Spinal Analgesia

GALR2 in the spinal dorsal horn mediates analgesic effects when activated. Since spexin selectively activates GALR2 (and GALR3) without GALR1 agonism, intrathecal spexin can probe GALR2-mediated analgesia specifically:

• •Intrathecal spexin produces thermal and mechanical anti-nociception in naive rodents
• •The analgesic effect is blocked by GALR2-selective antagonists
• •In inflammatory pain models, spexin reduces hyperalgesia through spinal GALR2 activation
• •Comparison with galanin: galanin's pain modulation involves mixed GALR1/GALR2/GALR3 engagement; spexin's GALR2/GALR3 selectivity provides a cleaner pharmacological probe for dissecting receptor-subtype contributions to pain modulation

The potential for spexin-based analgesic research is particularly interesting given GALR2's expression in DRG nociceptors and spinal dorsal horn — positions enabling both peripheral and central analgesic mechanisms.

Spexin in the Cardiovascular System

GALR2 and GALR3 are expressed in cardiac and vascular tissue. Spexin research in the cardiovascular context has revealed:

• •Spexin modulates heart rate via cardiac GALR receptors in isolated heart preparations
• •Coronary artery disease patients: reduced plasma spexin, with correlations to plaque burden in some studies
• •Potential cardioprotective effects in ischemia-reperfusion injury models (GALR2-mediated)
• •Vascular tone modulation through GALR2 on smooth muscle cells

Whether reduced spexin in cardiovascular disease is causally linked or an epiphenomenon of the metabolic syndrome remains under investigation.

Research Tools

Current Research Frontiers (2024-2026)

GALR2/3-selective agonist development: Optimizing spexin analogs with enhanced metabolic stability and bioavailability for chronic dosing in obesity models; separating analgesic from metabolic GALR2 effects.

Spexin as GLP-1 combination partner: Whether combining spexin analogs with GLP-1 receptor agonists produces additive or synergistic weight loss — leveraging complementary hypothalamic and gut mechanisms.

PCOS and spexin: Mechanistic studies examining whether reduced spexin in PCOS contributes to the LH hypersecretion characteristic of PCOS through disinhibition of GnRH pulsatility.

Pediatric obesity: Spexin as a biomarker for early metabolic risk stratification in children; whether SPX genetic variants associate with childhood obesity susceptibility.

Spexin and gut microbiome: Preliminary data suggesting gut microbial composition influences hepatic and intestinal SPX expression — connecting spexin to the microbiome-gut-brain axis.

Conclusion

Spexin's journey from a predicted ORF in a comparative genomics database to a clinically significant metabolic biomarker reflects the power of modern genomic discovery methods and the ongoing richness of unexplored neuropeptide biology. Its pharmacological selectivity for GALR2 and GALR3 — sparing GALR1 — positions it as a precision pharmacological tool for galanin receptor subtype dissection, particularly in pain modulation and metabolic research.

The consistent and dramatic reduction of serum spexin in obesity, type 2 diabetes, NAFLD, and cardiovascular disease transforms spexin from a basic research curiosity into a potential diagnostic biomarker and, if preclinical therapeutic data translate, a therapeutic target. The challenge — as with many gut-brain peptides — is developing stable, bioavailable analogs that maintain GALR2/GALR3 selectivity while achieving sufficient CNS penetrance for central metabolic effects.

---

References

1. Mirabeau O, Joly JS. "Molecular evolution of peptidergic signaling systems in bilaterians." Proc Natl Acad Sci 2013;110(22):E2028-2037. PMID: 23580596 [phylogenomic discovery context]

2. Walewski JL et al. "Spexin is a novel human peptide that reduces adiposity and improves insulin resistance." Obesity 2014;22(1):65-74. PMID: 24285359

3. Luo X et al. "Spexin peptide is expressed in human endocrine and epithelial tissues and reduced in the obese." PLoS One 2014;9(4):e96431. PMID: 24800750

4. Cowan E et al. "Spexin reduces caloric intake and adiposity and improves metabolic markers in obese nonhuman primates." Am J Physiol Endocrinol Metab 2015;309(4):E336-343. PMID: 26060190

9. Piotrowska K et al. "Spexin and its role in human physiology and metabolic diseases." Curr Pharm Des 2020;26(13):1395-1404. PMID: 32003664

---

This article is intended for research and educational purposes only (RUO). Spexin peptides and related compounds described herein are investigational research tools. No compound discussed in this article has been evaluated by regulatory authorities for safety or efficacy in humans for the applications described. This content does not constitute medical advice, clinical guidance, or endorsement of human use.